Viagra fights heart and lung diseases

German researchers have reported on the impact of Viagra on pulmonary hypertension at the Frontiers of Vascular Medicine Conference at Monash University this week.

High blood pressure in the vessels of the lung results in a dramatic reduction of quality of life and often to heart failure. There are limited treatments for pulmonary hypertension which causes 10 per cent of all cases of heart failure worldwide.

In 2004 Professors Friedrich Grimminger and Werner Seeger from the German University of Giessen Lung Centre showed Viagra protected mountain climbers' lungs from problems associated with high altitude.

This, and other discoveries by the German team led to the US Food and Drug Administration approving Viagra's active ingredient - sildenafil citrate - in June this year for the treatment of pulmonary hypertension.

Their latest trial, in rabbits, has shown Viagra not only lowers blood pressure but also regenerates diseased blood vessels.

The researchers now plan to enter into collaboration with Monash to bring their research to Australia.

Professor Harald Schmidt, one of the leaders of the German research, has been recruited to lead a new Australian attack on cardiovascular disease, as head of Monash University's Department of Pharmacology.

"Blood vessel diseases such as stroke, pulmonary hypertension, angina pectoris, myocardial infarction and coronary heart disease represent the number one cause of death worldwide," Professor Schmidt said.

"How these diseases develop is insufficiently understood. Consequently, only symptoms such as elevated blood pressure rather than causes of diseases can be treated. We need to do better."

There are plans to create a Centre of Excellence for Vascular Health at Monash, said Professor Warwick Anderson, head of the School of Biomedical Sciences .

The Frontiers of Vascular Medicine conference brings together researchers from German and US centres of excellence, the Baker Institute, RMIT, the University of Melbourne, the Australian Synchrotron, and many other Australian universities and institutes.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study: 40% of newly diagnosed heart failure patients also have atrial fibrillation